Status:
COMPLETED
Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
10-17 years
Phase:
PHASE3
Brief Summary
This trial is conducted in South Africa. The aim of this trial is to investigate Long term safety of biphasic insulin aspart 30 in juveniles with type 1 diabetes previously treated in trial BIAsp-1240...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Signed informed consent obtained before any trial-related activities according to local requirements. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
- The subject must have completed the trial BIAsp-1240
Exclusion
Key Trial Info
Start Date :
March 20 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2003
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01486381
Start Date
March 20 2002
End Date
May 30 2003
Last Update
February 24 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Pretoria, Gauteng, South Africa, 0001
2
Novo Nordisk Investigational Site
Cape Town, Western Cape, South Africa, 7925